Results about: protein aggregation
A high resolution description of the structure and dynamics of proteins is a very useful tool to study the properties and the function of these important biomacromolecules and, most importantly, to understand how changes in sequence or environment can lead to disease.
A study at IRB Barcelona sheds light on the dynamics of protein aggregates that behave like “droplets of oil in water” and that are described as membraneless cytoplasmic organelles.
These organelles regulate protein activity during cell division.
This is the first study at the Institute to address the so-called liquid-like droplets, which are attracting the attention of researchers worldwide.
New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease
Researchers at IRB Barcelona describe for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane.
What causes neuron death and the subsequent cognitive decline in Alzheimer´s disease is still unknown.
Kennedy’s disease leads to progressive muscle wastage. It is a condition that affects only men and it appears between 40 and 50 years of age. There is no specific treatment available.
In individuals with this disease, muscle cells and motor neurons die over the years because they accumulate a protein that is mutated.
Researchers at IRB Barcelona discover that this protein has a self-protective mechanism through which the deleterious effects of the mutation are delayed.
The findings of an IRB Barcelona study challenge a scientific principle about amyloid beta, a protein linked to Alzheimer’s disease
Natàlia Carulla’s research group provides information that questions the widely accepted premise regarding the number of molecules and the shape of the first aggregates formed by amyloid beta protein
Amyloid beta protein aggregation, the process by which molecules of this protein adhere to each other is strongly associated with the development of Alzheimer’s disease
Carulla’s work ultimately seeks to identify molecules that interfere with the initial stages of aggregation as a strategy to combat the disease.
On Friday 6 March in a conference at the CCCB, researcher Xavier Salvatella will explain the excellent moment being experienced by research into rare diseases.
Salvatella will present the breakthrough in his lab regarding Kennedy’s disease, a rare muscular atrophy that affects 1 in 36,000 men. “In five years’ time we could have a candidate drug tested in cells in vitro.”
This is the first of four conferences in the “Science today for the medicine of the future”, proposed by IRB Barcelona to explain the close link between basic research and medicine of the future, held on the occasion of the 10th anniversary of the centre.
The project, led by Natàlia Carulla, has been awarded funds from “La Marató de TV3” initiative held in 2013.
The project, which will be undertaken over three years, aims to verify a new therapeutic target to fight Alzheimer’s.
Scientists at IRB Barcelona in collaboration with researchers at the University of Barcelona observe that aggregates of 20 to 100 units of beta-amyloid have a structure that is the most harmful to neurons.
This is the first time that a method allows scientists to monitor aggregation while simultaneously detect a structural pattern responsible for the toxicity of beta-amyloid aggregation.
The researchers state that these studies are a step towards finding a therapeutic target for a disease which, to date, has no treatment.